Leerink analyst Marc Goodman started Acadia with a Market Perform and $21 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding Acadia, Goodman believes Nuplazid will rebound following the negative publicity regarding its safety profile based on his proprietary MEDACorp physician survey work, but consensus now assumes a rebound.